Premium
Topical use of calcitriol 3 µg/g ointment in the treatment of mild‐to‐moderate psoriasis: results from an open‐label study
Author(s) -
Carboni I,
De Felice C,
Bergamin A,
Chimenti S
Publication year - 2005
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2005.01331.x
Subject(s) - tolerability , medicine , calcitriol , psoriasis , adverse effect , vitamin d and neurology , body surface area , dermatology , pharmacology , gastroenterology
Background Calcitriol is the active metabolite and hormonal analogue of vitamin D 3 . It is widely used for the topical treatment of psoriasis showing good tolerability and effectiveness. Objectives To assess the efficacy, tolerability and safety of calcitriol 3 µg/g ointment in mild to moderate plaque psoriasis involving sensitive areas. Methods Sixty patients with a body surface area < 35% were enrolled into a prospective open label clinical study. Patients were treated for 12 weeks with a twice daily calcitriol 3 µg/g topical ointment application. Efficacy and safety were assessed during the therapy and during a 6‐month follow‐up period. Results The study demonstrated a high clinical remission rate which progressively increased throughout therapy (11.6% at week 4, 28.3% at week 8 and 63.3% at week 12). No serious adverse events and clinically relevant changes of calcium/phosphorus homeostasis were reported. Conclusions The study suggests that calcitriol 3 µg/g ointment, applied twice daily, is an effective topical treatment for chronic psoriatic plaques involving less than 35% of the body surface and sensitive areas.